Abstract
Disruption of the blood-spinal cord barrier (BSCB) and microvascular changes leading to reduction of blood supply represent hallmarks of spinal cord secondary injury causing further deterioration of the traumatized patient. Injury to the blood vessels starts with prominent hemorrhage and generation of inflammation. Furthermore, spinal cord ischemia and extravasation of blood components contribute to edema formation resulting in death of neural cells. Endogenous attempts of re-vascularization have been observed although these newly formed vessels display morphological and functional abnormalities. The unfavorable regulation of angiogenic and counterregulatory anti-angiogenic factors during the complicated course of vessel remodeling after SCI is suspected to participate in the failure of re-vascularization and vessel stabilization. Repression of the expression of angiogenic factors such as vascular endothelial growth factor-A (VEGF-A), placental growth factor (PlGF), angiopoietin-1 (Ang1), and platelet-derived growth factor-BB (PDGF-BB) contributes to vessel regression. Therefore, therapeutic applications of angiogenic factors following SCI are promising strategies to restore blood flow in the lesion.
Keywords: Angiogenic factors, angiogenesis, blood vessels., cell-based therapy, re-vascularization, spinal cord injury, blood-spinal cord barrier (BSCB), autoregulation, small anastomoses, traumatic brain injury, neoangiogenesis, Endothelial monocyte-activating polypeptide, progenitor cell, oligodendrocyte, Multipotent, traumatic injuries
Current Neurovascular Research
Title: Necessity for Re-Vascularization after Spinal Cord Injury and the Search for Potential Therapeutic Options
Volume: 8 Issue: 4
Author(s): Ursula Graumann, Marie-Francoise Ritz and Oliver Hausmann
Affiliation:
Keywords: Angiogenic factors, angiogenesis, blood vessels., cell-based therapy, re-vascularization, spinal cord injury, blood-spinal cord barrier (BSCB), autoregulation, small anastomoses, traumatic brain injury, neoangiogenesis, Endothelial monocyte-activating polypeptide, progenitor cell, oligodendrocyte, Multipotent, traumatic injuries
Abstract: Disruption of the blood-spinal cord barrier (BSCB) and microvascular changes leading to reduction of blood supply represent hallmarks of spinal cord secondary injury causing further deterioration of the traumatized patient. Injury to the blood vessels starts with prominent hemorrhage and generation of inflammation. Furthermore, spinal cord ischemia and extravasation of blood components contribute to edema formation resulting in death of neural cells. Endogenous attempts of re-vascularization have been observed although these newly formed vessels display morphological and functional abnormalities. The unfavorable regulation of angiogenic and counterregulatory anti-angiogenic factors during the complicated course of vessel remodeling after SCI is suspected to participate in the failure of re-vascularization and vessel stabilization. Repression of the expression of angiogenic factors such as vascular endothelial growth factor-A (VEGF-A), placental growth factor (PlGF), angiopoietin-1 (Ang1), and platelet-derived growth factor-BB (PDGF-BB) contributes to vessel regression. Therefore, therapeutic applications of angiogenic factors following SCI are promising strategies to restore blood flow in the lesion.
Export Options
About this article
Cite this article as:
Graumann Ursula, Ritz Marie-Francoise and Hausmann Oliver, Necessity for Re-Vascularization after Spinal Cord Injury and the Search for Potential Therapeutic Options, Current Neurovascular Research 2011; 8 (4) . https://dx.doi.org/10.2174/156720211798121007
DOI https://dx.doi.org/10.2174/156720211798121007 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Induced Adaptive Resistance to Nitrooxidative Stress in the CNS: Therapeutic Implications
Central Nervous System Agents in Medicinal Chemistry Inflammation in Neurodegenerative Disorders: Friend or Foe?
Current Aging Science Gap Junctions as Therapeutic Targets in Brain Injury Following Hypoxia- Ischemia
Recent Patents on CNS Drug Discovery (Discontinued) Alpha9Alpha10 Nicotinic Acetylcholine Receptors as Target for the Treatment of Chronic Pain
Current Pharmaceutical Design The Multiple Aspects of Stroke and Stem Cell Therapy
Current Molecular Medicine Prodrugs and Endogenous Transporters: Are They Suitable Tools for Drug Targeting into the Central Nervous System?
Current Pharmaceutical Design The Role of T-Type Calcium Channels in Peripheral and Central Pain Processing
CNS & Neurological Disorders - Drug Targets Current Management and Treatment of Cerebral Vasospasm Complicating SAH
CNS & Neurological Disorders - Drug Targets Management of Spasticity in Progressive Multiple Sclerosis: Efficacy of Repeated Intrathecal Triamcinolone Acetonide Administration
Current Pharmaceutical Design Piroxicam: Source for Synthesis of Central Nervous System (CNS) Acting Drugs
Central Nervous System Agents in Medicinal Chemistry FTIR Spectroscopy Analysis can Highlight Induced Damage in Neuronallike Cells and Bio-protective Effectiveness of Agmatine
Current Metabolomics CXCR2 Receptor Antagonists: A Medicinal Chemistry Perspective
Current Topics in Medicinal Chemistry CCR1 and CCR2 Antagonists
Current Topics in Medicinal Chemistry New Drugs for Epidural Analgesia
Current Drug Targets Challenges in Small Screening Laboratories: Implementing an On-Demand Laboratory Information Management System
Combinatorial Chemistry & High Throughput Screening Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets Neural Stem Cells Transplanted in a Mouse Model of Parkinson’s Disease Differentiate to Neuronal Phenotypes and Reduce Rotational Deficit
CNS & Neurological Disorders - Drug Targets Motor Neuron Disease and Acquired Axonal Neuropathy Association in HIV Infection: Case Report and Update
Current HIV Research SLC1 Glutamate Transporters and Diseases: Psychiatric Diseases and Pathological Pain
Current Molecular Pharmacology Modulation of Stem Cell Differentiation by the Influence of Nanobiomaterials/ Carriers
Current Stem Cell Research & Therapy